MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=95213&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on MacroGenics, Inc.(MGNX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK , Aug. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline

RADNOR, PA / ACCESSWIRE / August 11, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

MGNX REMINDER: Kessler Topaz Meltzer & Check, LLP Urges MGNX Investors with Losses to Contact the Firm

RADNOR, PA / ACCESSWIRE / August 10, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

MacroGenics Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

Investors Can Take The Lead In The MacroGenics Inc Securities Fraud Lawsuit With The Schall Law Firm

RADNOR, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is September 24, 2024.

Class Action Announcement for MacroGenics, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against MacroGenics, Inc. - Contact Kessler Topaz Meltzer & Check, LLP

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”), of the important September 24, 2024 lead plaintiff deadline.

ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX

RADNOR, PA / ACCESSWIRE / August 9, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

Important September 24, 2024 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Investors of Securities Fraud Class Action Lawsuit

Hagens Berman Encourages MGNX Investors with Substantial Losses to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / August 9, 2024 / Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 - May 9, 2024 Lead Plaintiff Deadline: Sept.

MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman

RADNOR, Pa. , Aug. 8, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024.

MGNX Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges MGNX Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

Investors Have Opportunity To Lead MacroGenics Inc Securities Fraud Lawsuit With The Schall Law Firm

NEW YORK , Aug. 8, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights - MGNX

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

MGNX Investors Can Take The Lead In The MacroGenics Inc Securities Fraud Lawsuit With The Schall Law Firm

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics, Inc. Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against MGNX

SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX). If you incurred significant losses and want to act as the lead plaintiff in the MacroGenics class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: March 7, 2024 to May 9, 2024 LEAD PLAINTIFF DEADLINE: September 24, 2024 DOCKET #: 24-CV-02184 (D.

MacroGenics (MGNX) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action

SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ:MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v.

MGNX INVESTOR DEADLINE: MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=94212&wire=1 or contact Joseph E. Levi, Esq.

MacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MGNX

MacroGenics (MGNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

MGNX Investors Have Opportunity To Lead MacroGenics Inc Securities Fraud Lawsuit With The Schall Law Firm

ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2024.

MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

Hagens Berman Encourages MGNX Investors with Substantial Losses to Contact Firm SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2024 / Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 - May 9, 2024 Lead Plaintiff Deadline: Sept.

MacroGenics (MGNX) Faces Class Action After Revealing Investigation of Patient Deaths in TAMARACK Study of Vobra Duo – Hagens Berman

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) --  The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics as well as MacroGenics' Chief Executive Officer with violations of the Securities Exchange Act of 1934.

MGNX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: MacroGenics business and prospects, resulting in its stock trading at inflated prices.

MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

News for MacroGenics Stock (MGNX)